Table 1. Overall analysis between hOGG1 Ser326Cys polymorphism and risk of cancer.
| Cancers | No. of studies | Heterogeneity | Model | OR (95% CI) | p | |
|---|---|---|---|---|---|---|
| p | I-squared | |||||
| C vs. G | ||||||
| All cancers | 125 | <0.001 | 61. 138 | Random | 1.092 (1.051-1.134) | <0.001 |
| Colorectal cancer | 17 | <0.001 | 65.928 | Random | 1.121 (1.005-1.251) | 0.040 |
| Lung cancer | 28 | <0.001 | 51.835 | Random | 1.094 (1.020-1.172) | 0.012 |
| Breast cancer | 16 | 0.077 | 35.7 | Fixed | 1.031 (0.985-1.079) | 0.185 |
| Bladder cancer | 4 | 0.004 | 77.187 | Random | 1.058 (0.812-1.379) | 0.676 |
| Gallbladder cancer | 2 | 0.015 | 83.061 | Random | 1.044 (0.877-1.242) | 0.627 |
| Prostate cancer | 6 | <0.001 | 79.676 | Random | 1.459 (1.068-1.992) | 0.018 |
| Gastric cancer | 13 | 0.034 | 46.33 | Random | 1.011 (0.883-1.157) | 0.874 |
| Esophageal cancer | 10 | 0.112 | 37.044 | Fixed | 1.050 (0.957-1.152) | 0.299 |
| Head and neck cancer | 8 | <0.001 | 77.552 | Random | 1.335 (1.079-1.651) | 0.008 |
| Hepatocellular cancer | 7 | <0.001 | 74.985 | Random | 1.089 (0.883-1.344) | 0.424 |
| Acute lymphoblastic leukemia | 2 | 0.002 | 89.539 | Random | 1.579 (0.775-3.217) | 0.208 |
| Pancreatic adenocarcinoma | 2 | 0.467 | <0.001 | Fixed | 1.007 (0.885-1.146) | 0.917 |
| C/C vs. C/G+G/G | ||||||
| All cancers | 127 | <0.001 | 56.428 | Random | 1.079 (1.027-1.134) | 0.002 |
| Colorectal cancer | 18 | <0.001 | 60.869 | Random | 1.140 (0.993-1.308) | 0.063 |
| Lung cancer | 28 | 0.004 | 47.036 | Random | 1.080 (0.984-1.187) | 0.106 |
| Breast cancer | 16 | 0.202 | 22.109 | Fixed | 1.011 (0.948-1.078) | 0.742 |
| Bladder cancer | 4 | 0.39 | 0.312 | Fixed | 1.000 (0.847-1.181) | 0.996 |
| Gallbladder cancer | 2 | 0.029 | 78.918 | Random | 1.080 (0.644-1.812) | 0.771 |
| Prostate cancer | 7 | <0.001 | 75.606 | Random | 1.401 (0.976-2.011) | 0.067 |
| Gastric cancer | 13 | 0.346 | 9.913 | Fixed | 0.928 (0.821-1.048) | 0.229 |
| Esophageal cancer | 10 | 0.199 | 26.588 | Fixed | 0.971 (0.854-1.104) | 0.652 |
| Head and neck cancer | 8 | <0.001 | 74.243 | Random | 1.424 (1.099-1.845) | 0.007 |
| Hepatocellular cancer | 7 | <0.001 | 88.181 | Random | 1.113 (0.673-1.841) | 0.677 |
| Acute lymphoblastic leukemia | 2 | 0.006 | 86.606 | Random | 1.401 (0.583-3.364) | 0.451 |
| Pancreatic adenocarcinoma | 2 | 0.451 | <0.001 | Fixed | 1.051 (0.898-1.230) | 0.539 |
| C/C+C/G vs. G/G | ||||||
| All cancers | 125 | <0.001 | 54.586 | Random | 1.178 (1.098-1.263) | <0.001 |
| Colorectal cancer | 17 | 0.04 | 41.096 | Random | 1.154 (0.959-1.388) | 0.129 |
| Lung cancer | 28 | 0.03 | 36.264 | Random | 1.188 (1.055-1.337) | 0.004 |
| Breast cancer | 16 | 0.378 | 6.626 | Fixed | 1.092 (1.004-1.189) | 0.041 |
| Bladder cancer | 4 | <0.001 | 86.372 | Random | 1.118 (0.557-2.246) | 0.753 |
| Gallbladder cancer | 2 | 0.074 | 68.567 | Fixed | 1.099 (0.761-1.585) | 0.615 |
| Prostate cancer | 6 | 0.003 | 72.07 | Random | 1.691 (0.965-2.965) | 0.066 |
| Gastric cancer | 13 | 0.037 | 46.74 | Random | 1.088 (0.823-1.438) | 0.553 |
| Esophageal cancer | 10 | 0.02 | 54.195 | Random | 1.252 (0.929-1.686) | 0.139 |
| Head and neck cancer | 8 | 0.009 | 62.394 | Random | 1.551 (1.045-2.301) | 0.029 |
| Hepatocellular cancer | 7 | <0.001 | 85.472 | Random | 1.126 (0.723-1.754) | 0.600 |
| Acute lymphoblastic leukemia | 2 | 0.011 | 84.554 | Random | 2.435 (0.632-9.376) | 0.196 |
| Pancreatic adenocarcinoma | 2 | 0.809 | <0.001 | Fixed | 0.823 (0.578-1.172) | 0.280 |
OR odds ratio, vs versus. Bold numbers indicate significant association with risk of cancer.